Drugs / eN-Lac®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01116778 | May 2010 → Jan 2012 | perennial allergic rhinitis | GenMont Biotech Incorporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eN-Lac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01116778 ↗ |
| Known as | eN-Lac Capsules (Lactobacillus paracasei GMNL-32) | “eN-Lac® Capsules (Lactobacillus paracasei GMNL-32)” NCT01116778 ↗ |
| Modality | Other / unclassified | “probiotics eN-Lac® capsules” NCT01116778 ↗ |
| Route | Oral | “once daily, po” NCT01116778 ↗ |